Folate promotes colorectal cancer progression by impairing CD8+ T cell function and recruitment via SLC19A1/p-AKT/NOTCH1 axis and CCL5 downregulation - PubMed
5 hours ago
- #folate
- #colorectal-cancer
- #immunotherapy
- Folate supplementation promotes colorectal cancer (CRC) growth by impairing CD8+ T cell function and recruitment.
- Mechanistically, folate enhances SLC19A1 expression, leading to AKT phosphorylation and activation of NOTCH1 signaling, causing T cell exhaustion.
- Folate in the tumor microenvironment suppresses PBX3 expression, reducing CCL5 transcription and hindering CD8+ T cell recruitment.
- Dietary folate restriction enhances tumor control and synergizes with anti-PD-1 immunotherapy in CRC.
- The study suggests folate may facilitate CRC progression and immune evasion, offering insights for potential nutritional and immunotherapy interventions.